General mechanisms of coagulation and targets of anticoagulants (Section I)

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Thrombosis and Haemostasis

• Publication date

  2013-02-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1160/TH12-10-0772PMID 23447024
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anticoagulation versus placebo for heart failure in sinus rhythm.

  2014cited by this paper
• Inflammation, Atherosclerosis and Coronary Artery Disease

  2014cited by this paper
• [Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)].

  2013cited by this paper
• Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Warfarin and aspirin in patients with heart failure and sinus rhythm.

  2012cited by this paper
• Lufaxin, a Novel Factor Xa Inhibitor From the Salivary Gland of the Sand Fly Lutzomyia longipalpis Blocks Protease-Activated Receptor 2 Activation and Inhibits Inflammation and Thrombosis In Vivo

  2012cited by this paper
• New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.

  2012influential reference
• Guidelines on the management of valvular heart disease (version 2012).

  2012cited by this paper
• Sources of tissue factor that contribute to thrombosis after rupture of an atherosclerotic plaque.

  2012cited by this paper
• Vorapaxar in the secondary prevention of atherothrombotic events.

  2012cited by this paper
• Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

  2012cited by this paper
• Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).

  2012cited by this paper
• 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.

  2012cited by this paper
• Tissue factor/TFPI and blood cells.

  2012cited by this paper
• Antithrombotic Management in Patients with Prosthetic Valves

  2012cited by this paper
• Microparticles as a circulating source of procoagulant and fibrinolytic activities in the circulation.

  2012cited by this paper
• Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012influential reference
• Cellular Mechanisms Underlying the Formation of Circulating Microparticles

  2011cited by this paper
• Bleeding risk assessment and management in atrial fibrillation patients

  2011cited by this paper
• Ischaemic stroke and bleeding rates in ‘real-world’ atrial fibrillation patients

  2011cited by this paper
• Factor Xa and thrombin as targets for new oral anticoagulants.

  2011cited by this paper
• Thromboembolism and antithrombotic therapy in patients with heart failure in sinus rhythm: current status and future directions.

  2011cited by this paper
• Factor XI and XII as antithrombotic targets

  2011cited by this paper
• Inflammation and coagulation. An overview.

  2011cited by this paper
• Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study

  2011cited by this paper
• Antiplatelet agents for the treatment and prevention of atherothrombosis.

  2011cited by this paper
• Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients

  2011cited by this paper
• Microparticles, Vascular Function, and Atherothrombosis

  2011cited by this paper
• Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis.

  2011influential reference
• Arterial thrombus formation in cardiovascular disease

  2011cited by this paper
• Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE

  2011cited by this paper
• Apixaban in patients with atrial fibrillation.

  2011cited by this paper
• Warfarin use and outcomes in patients with advanced chronic systolic heart failure without atrial fibrillation, prior thromboembolic events, or prosthetic valves.

  2011cited by this paper
• Characterization of the proportion of untreated and antiplatelet therapy treated patients with atrial fibrillation.

  2011cited by this paper
• Tissue factor and thrombosis: The clot starts here

  2010cited by this paper
• Cellular sources of tissue factor in endotoxemia and sepsis.

  2010cited by this paper
• New insights into the structural elements involved in the skin haemorrhage induced by snake venom metalloproteinases

  2010cited by this paper
• Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk

  2010cited by this paper
• Underuse of oral anticoagulants in atrial fibrillation: a systematic review.

  2010cited by this paper
• New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs

  2010cited by this paper
• Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence

  2010cited by this paper
• Tissue factor in cardiovascular disease pathophysiology and pharmacological intervention.

  2010cited by this paper
• Inflammation and coagulation

  2010cited by this paper
• Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited.

  2009cited by this paper
• Systolic Heart Failure: A Prothrombotic State

  2009cited by this paper
• Human alternatively spliced tissue factor is not secreted and does not trigger coagulation

  2009cited by this paper
• What is the appropriate approach to prevention of thromboembolism in heart failure?

  2009cited by this paper
• Protein S as Cofactor for TFPI

  2009cited by this paper
• The Impact of the Fibrinolytic System on the Risk of Venous and Arterial Thrombosis

  2009cited by this paper
• Aniticoagulation in patients following prosthetic heart valve replacement.

  2009cited by this paper
• Impact of Chronic Antithrombotic Therapy on Hospital Course of Patients with Acute Myocardial Infarction

  2009cited by this paper
• Vascular smooth muscle-derived tissue factor is critical for arterial thrombosis after ferric chloride-induced injury.

  2009cited by this paper
• Thrombogenesis in atrial fibrillation contributing mechanisms and natural history

  2008cited by this paper
• Heparin and low-molecular-weight heparin

  2008cited by this paper
• Thrombogenesis in atrial fibrillation: contributing mechanisms and natural history

  2008cited by this paper
• The haemostatic role of tissue factor pathway inhibitor.

  2007cited by this paper
• Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial.

  2007cited by this paper
• Guidelines on the management of valvular heart disease.

  2007cited by this paper
• TF/FVIIa Transactivate PDGFR&bgr; to Regulate PDGF-BB–Induced Chemotaxis in Different Cell Types: Involvement of Src And PLC

  2007cited by this paper
• Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy.

  2007cited by this paper
• Guidelines on the management of valvular heart disease The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology

  2007cited by this paper
• Anticoagulants in heart disease: current status and perspectives.

  2007cited by this paper
• Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.

  2006cited by this paper
• Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor.

  2006influential reference
• A cell-based model of thrombin generation.

  2006cited by this paper
• Tissue factor pathway inhibitor: structure, biology and involvement in disease

  2006cited by this paper
• What does it take to make the perfect clot?

  2006cited by this paper
• Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall.

  2005cited by this paper
• Venous and arterial thrombosis: a continuous spectrum of the same disease?

  2005cited by this paper
• Atherothrombosis and high-risk plaque: part I: evolving concepts.

  2005cited by this paper
• Inflammation, atherosclerosis, and coronary artery disease.

  2005cited by this paper
• Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation.

  2005cited by this paper
• Protease‐activated receptors in hemostasis, thrombosis and vascular biology

  2005influential reference
• Two-way interactions between inflammation and coagulation.

  2005cited by this paper
• Crosstalk between inflammation and thrombosis.

  2004influential reference
• Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cited by this paper
• Regulation of angiogenesis by tissue factor cytoplasmic domain signaling

  2004cited by this paper
• Regulation of chemotaxis by the cytoplasmic domain of tissue factor

  2004cited by this paper
• Tissue factor-factor VIIa signaling.

  2004cited by this paper
• What is all that thrombin for?

  2003cited by this paper
• Thrombin‐activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)

  2003cited by this paper
• Specificity of coagulation factor signaling

  2003cited by this paper
• Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.

  2003cited by this paper
• Thrombin formation.

  2003cited by this paper
• Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor

  2003cited by this paper
• A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS).

  2002influential reference
• Platelets and thrombin generation.

  2002cited by this paper
• Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE).

  2002cited by this paper
• Activation of Endothelial Cell Protease Activated Receptor 1 by the Protein C Pathway

  2002influential reference
• A Cell-based Model of Hemostasis

  2001cited by this paper
• Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.

  2001cited by this paper
• Anticoagulation for heart failure in sinus rhythm.

  2000cited by this paper
• Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty.

  2000cited by this paper
• Blood coagulation.

  2000cited by this paper
• The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment.

  2000cited by this paper
• Management of Acute Coronary Syndromes

  1999cited by this paper
• Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice.

  1998cited by this paper
• Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction

  1998cited by this paper

• Chemical characterization, toxicity and involvement of calmodulin in the antithrombotic activity of Rosmarinus officinalis L. essential oil

  2026cites this paper
• Reduction of Thrombus Burden With Short‐Term, Low‐Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE‐ARMYDA 7 Randomized Trial

  2025cites this paper
• Application of Human Genetics to Prioritize Coagulation Cascade Protein Targets for Ischemic Stroke Prevention

  2025cites this paper
• EFFECTS OF MILVEXIAN ALONE OR WITH HEPARIN ON CATHETER-INDUCED CLOTTING AND THROMBIN GENERATION.

  2025cites this paper
• Cerebral Microbleeds Associate with Brain Endothelial Cell Activation-Dysfunction and Blood–Brain Barrier Dysfunction/Disruption with Increased Risk of Hemorrhagic and Ischemic Stroke

  2024cites this paper
• Layered Double Hydroxides: Recent Progress and Promising Perspectives Toward Biomedical Applications

  2024cites this paper
• Isolation, structural characterization and biological activities of polysaccharides from Chondrus crispus

  2024cites this paper
• Anti – intercellular adhesion molecule-1(ICAM-1) nanoparticles for damaged endothelium to treat venous thromboembolism

  2024cites this paper
• A review of the impact, pathophysiology, and management of atrial fibrillation in patients with heart failure with preserved ejection fraction

  2023cites this paper
• Peripheral artery disease: Update on etiology, pathophysiology, diagnosis and treatment.

  2023cites this paper
• Safety and Efficacy of Novel Oral Anticoagulants as Compared to Warfarin in Treatment of Atrial Fibrillation

  2023cites this paper
• Bivalirudin in acute coronary syndromes

  2023cites this paper
• Synthetic coumarin derivatives with anticoagulation and antiplatelet aggregation inhibitory effects

  2023cites this paper
• Hemorrhagic Fever with Renal Syndrome in Asia: History, Pathogenesis, Diagnosis, Treatment, and Prevention

  2023cites this paper
• Fluorescent Activity-Based Probe To Image and Inhibit Factor XIa Activity in Human Plasma

  2023cites this paper
• Potential anticoagulant of traditional chinese medicine and novel targets for anticoagulant drugs.

  2023cites this paper
• A journey to vasculopathy in systemic sclerosis: focus on haemostasis and thrombosis

  2023cites this paper
• Current update on herbal sources of antithrombotic activity—a comprehensive review

  2022cites this paper
• Real‐life contemporary vitamin K antagonist is still associated with very low time in therapeutic range despite strict international normalized ratio monitoring: Results of big data analysis

  2022cites this paper
• Fibrin Sealants: Challenges and Solutions.

  2022cites this paper
• Magnitude of Coagulation Abnormalities and Associated Factors Among Patients with Heart Diseases at the University of Gondar Comprehensive Specialized Hospital

  2022cites this paper
• The Central Role of Extracellular Vesicles in the Mechanisms of Thrombosis in COVID-19 Patients With Cancer and Therapeutic Strategies

  2022cites this paper
• Anticoagulant use to treat VTE (venous thromboembolism) in pregnancy: a review

  2022cites this paper
• Phytochemistry, pharmacological activity, and potential health benefits of Glycyrrhiza glabra

  2021cites this paper
• Thrombin: A Pivotal Player in Hemostasis and Beyond

  2021cites this paper
• Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation

  2021cites this paper
• Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation

  2021cites this paper
• Retrospective cohort study of new-onset atrial fibrillation in acute pulmonary embolism on prognosis

  2021cites this paper
• ANTI-COAGULANT PROPERTIES OF FLAVONOID COMPOUNDS: POTENTIAL STRUCTURE-FUNCTIONAL RELATIONSHIP

  2021cites this paper
• Thromboembolism in Malignant Musculoskeletal Tumour: A Literature Review

  2021cites this paper
• Inflammatory Biomarkers in the Short-Term Prognosis of Venous Thromboembolism: A Narrative Review

  2021cites this paper
• Predictors of Optimum AntiCoagulation in a Mechanical Heart Valve Replacement Population

  2021influential citation
• Management of prosthetic valve thrombosis complicated by ischemic stroke in pregnancy

  2020cites this paper
• New oral anticoagulants for nonvalvular atrial fibrillation with stable coronary artery disease: A meta‐analysis

  2020cites this paper
• Evaluation of the Validity of SAMe-TT2R2 Score in a Cohort of Venous Thromboembolism Patients Treated With Warfarin

  2020cites this paper
• New oral anticoagulants for nonvalvular atrial fibrillation with peripheral artery disease: a meta-analysis

  2020cites this paper
• Structure-Activity Relationship Study of a Potent α-Thrombin Binding Aptamer Incorporating Hexitol Nucleotides.

  2020cites this paper
• Urea as the best fibrin solubilizer in the thrombin inhibition analysis: Theoretical and experimental modeling of fibrinogen denaturation

  2020cites this paper
• Is Holmium Laser Enucleation of the Prostate a Good Surgical Alternative in Benign Prostatic Hyperplasia Management? A Review Article.

  2020cites this paper
• Anticoagulant activity screening of an in-house database of natural compounds for discovering novel selective factor Xa inhibitors; a combined in silico and in vitro approach

  2020cites this paper
• Management of prosthetic valve thrombosis complicated by ischemic stroke in pregnancy

  2020cites this paper
• Management of prosthetic valve thrombosis complicated by ischemic stroke in pregnancy

  2020cites this paper
• Management of prosthetic valve thrombosis complicated by ischemic stroke in pregnancy

  2020cites this paper
• The influence of sodium citrate on the characteristics and biological activity of plasma rich in growth factors.

  2020cites this paper
• Flow Cytometric Assessment of Endothelial and Platelet Microparticles in Patients With Atrial Fibrillation Treated With Dabigatran

  2020cites this paper
• IL-33 / ST2 Signaling Promotes TF Expression by Regulating NF-κB Activation in Coronary Artery Endothelial Microparticles

  2020cites this paper
• Meta-Analysis of Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin According to Time in Therapeutic Range in Atrial Fibrillation.

  2020cites this paper
• Perioperatives Bridgingmanagement von Antikoagulation und Thrombozytenaggregationshemmung bei neurochirurgischen Eingriffen

  2020influential citation
• A Mini-Review: Clinical Development and Potential of Aptamers for Thrombotic Events Treatment and Monitoring

  2019cites this paper
• Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome

  2019cites this paper
• Development of New Antithrombotic Regimens for Patients with Acute Coronary Syndrome

  2019cites this paper
• Management of prosthetic valve thrombosis complicated by ischemic stroke in pregnancy.

  2019cites this paper
• Anticoagulant and antithrombotic effects of chemically sulfated guar gum.

  2019cites this paper
• In Vitro Antiatherothrombotic Effects of Extracts from Berberis Vulgaris L., Teucrium Polium L., and Orthosiphon Stamineus Benth

  2019cites this paper
• Isolation and purification of anticoagulant enzymes from plant latex

  2019cites this paper
• Antidotes for reversal of direct oral anticoagulants.

  2019cites this paper
• Direct-Acting Oral Anticoagulants (DOACs) in Cirrhosis and Cirrhosis-Associated Portal Vein Thrombosis

  2019cites this paper
• Role of endothelial dysfunction in relation to prothrombogenesis in polycythemia vera

  2018cites this paper
• Management of Various Bleeding Problems in Dental Patients: An Approach to Normal Hemostatic System and the Patient's Specific Coagulation Defect

  2018cites this paper
• The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations

  2018cites this paper
• Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases

  2018cites this paper
• What is the importance of real-time three dimensional transesophageal echocardiography and time in therapeutic range in patients with prosthetic valve thrombosis?

  2018cites this paper
• Clinical effects with inhibition of multiple coagulative pathways in patients admitted for acute coronary syndrome

  2018cites this paper
• Structural Basis for Activity and Specificity of an Anticoagulant Anti-FXIa Monoclonal Antibody and a Reversal Agent.

  2018cites this paper
• Construction of a small-caliber tissue-engineered blood vessel using icariin-loaded β-cyclodextrin sulfate for in situ anticoagulation and endothelialization

  2018cites this paper
• Non-vitamin K Antagonist Oral Anticoagulant After Acute Coronary Syndrome: Is There a Role?

  2018cites this paper
• The First Intrinsic Tenase Complex Inhibitor with Serine Protease Structure Offers a New Perspective in Anticoagulant Therapy

  2018cites this paper
• Dental management of patients with inherited bleeding disorders: a multidisciplinary approach.

  2017cites this paper
• Inhibition of plasmin generation in plasma by heparin, low molecular weight heparin, and a covalent antithrombin–heparin complex

  2017cites this paper
• Antithrombotic therapy for acute coronary syndrome: Past, present and future

  2017cites this paper
• Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians

  2017cites this paper
• Characterizing reactive glutamines in fibrinogen and elucidating factor XIII substrate specificity.

  2017cites this paper
• Anticoagulants for Atrial Fibrillation

  2017cites this paper
• The prothrombotic state in atrial fibrillation : observations on fibrin clot structure and the relationship to renal dysfunction

  2017cites this paper
• Medicinal plants with antithrombotic property in Persian medicine: a mechanistic review

  2017cites this paper
• The role of oral anticoagulant therapy in patients with acute coronary syndrome

  2017cites this paper
• University of Groningen Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data

  2017influential citation
• Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation

  2017cites this paper
• Integrating genotypes in the SAMe-TT2R2 score for the prediction of anticoagulation control in Chinese patients with atrial fibrillation on warfarin.

  2017cites this paper
• Factor XIa–specific IgG and a reversal agent to probe factor XI function in thrombosis and hemostasis

  2016cites this paper
• Drug-drug interactions of non-vitamin K oral anticoagulants

  2016cites this paper
• Coagulation Studies in Preoperative Neurosurgery Patients

  2016cites this paper
• Balancing risks and benefits in the optimization of oral antithrombotic therapy

  2016cites this paper
• Contemporary developments in the discovery of selective factor Xa inhibitors: A review.

  2016cites this paper
• Edoxabán. Propiedades farmacocinéticas y farmacodinámicas

  2016cites this paper
• Individualized approaches to thromboprophylaxis in atrial fibrillation.

  2016cites this paper
• New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?

  2016cites this paper
• Usefulness of the SAME-TT2R2 score to predict anticoagulation control on VKA in patients with atrial fibrillation and obstructive sleep apnea.

  2016cites this paper
• Stroke Prevention in Atrial Fibrillation: Focus on Latin America

  2016cites this paper
• Potential mechanism of acute stent thrombosis with bivalirudin following percutaneous coronary intervention in acute coronary syndromes.

  2016cites this paper
• Tissue factor is induced by interleukin-33 in human endothelial cells: a new link between coagulation and inflammation

  2016cites this paper
• Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges.

  2016cites this paper
• Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?

  2016cites this paper
• The melding of nanomedicine in thrombosis imaging and treatment: a review

  2016cites this paper
• Studies on interfaces between primary and secondary hemostasis

  2016cites this paper
• Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease

  2016cites this paper
• Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation.

  2016cites this paper
• Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications

  2016cites this paper
• Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.

  2016cites this paper
• Editors’ Choice 2015 papers in Thrombosis and Haemostasis

  2016cites this paper